The Business Case for Adherence: A Win for Pharma Is A Win For Patients
This article was originally published in RPM Report
Executive Summary
Low rates of patient adherence to medical therapy has been a persistent policy hurdle that has significant commercial implications for drug makers. The health reform debate taking place in Washington should include a solution to the problem-but pharma shouldn't take the lead.
You may also be interested in...
Obamacare: The Politics of Health Care Reform Entering the Endgame
There are multiple political strategies playing out in Washington on health care reform that will directly impact the biopharma industry. In the end biopharma will trade margins for volume. The RPM Report makes predictions on what will make it into the final health reform bill.
Predicting Health Reform: A Quick Guide To What Will Be In-and What Won't
The health care reform debate is entering the critical phase. Here are our predictions for where the legislation will end up.
BioPharma and Health Reform: The Good, the Bad, and the Just Plain Ugly
While the prospects for major health reform are unclear, there is more clarity to what biopharma has at stake: A lot. In this issue, The RPM Report presents a guide to the upsides and downsides for the biopharma industry of some of the major issues in health reform and some handicapping of the likelihood of each.